Locally Advanced or Metastatic Breast Cancer positive for estrogen-receptor (ER) and/or progesterone receptor (PgR) and negative for HER2 which is refractory to non-steroidal aromatase inhibitor (letrozole and/or anastrozole) MedDRA version: 16.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864
Conditions
Interventions
Product Code: BI 836845
Pharmaceutical Form: Concentrate for solution for injection/infusion
INN or Proposed INN: not yet assigned
Current Sponsor code: BI 836845
Other descriptive name: BI 836845
Con
Sponsors
Boehringer Ingelheim España, S.A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Histologically-confirmed locally advanced (aBC) or metastatic breast cancer (mBC) not deemed amenable to curative surgery or curative radiation therapy -Tumors are positive for estrogen-receptor (ER) and/or progesterone receptor (PgR). -Tumors must be negative for HER2 per local lab testing. -Must have adequate archival tumor tissue from surgery or biopsy. - Postmenopausal women. -Objective evidence of recurrence or progressive disease on or after the last line of systemic therapy for breast cancer prior to study entry - The patient is disease refractory to non-steroidal aromatase inhibitor (letrozole and/or anastrozole) - Patients must have measurable lesion according to RECIST version 1.1 or bone lesions only: lytic or mixed (lytic + sclerotic) in the absence of measurable lesion as defined above - Eastern Cooperative Oncology Group performance score = 6 months in the opinion of the investigator - Fasting plasma glucose =65 years) yes F.1.3.1 Number of subjects for this age range 63
Exclusion criteria
Exclusion criteria: - Previous treatment with agents targeting on IGF pathway, phosphoinositide 3-kinase (PI3K) signaling pathway, protein kinase B (AKT), or mammalian target of rapamycin (mTOR) pathways - Prior treatment with exemestane - Known hypersensitivity to monoclonal antibody, mTOR inhibitors (e.g. sirolimus), or to the excipients of any study drugs - Ovarian suppression by ovarian radiation or treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist - Less than one week after receiving immunization with attenuated live vaccines prior to study treatment - Radiotherapy within 4 weeks prior to run-in treatment, except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within two weeks prior to study treatment - Chemotherapy, biological therapy (other than bevacizumab), immunotherapy or investigational agents within 5 half-life of the drug or within two weeks prior to the start of study treatment, whichever is longer; bevacizumab treatment within 4 weeks prior to start of study treatment - Hormonal treatment for breast cancer within 2 weeks prior to start of study treatment - Major surgery in the judgement of the investigator within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study - Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use except Topical applications, inhaled sprays, eye drops or local injections or Patients on stable low dose of corticosteroids for at least two weeks before study entry - Chronic hepatitis B infection, chronic hepatitis C infection and/or known HIV carrier - QTcF prolongation > 470 ms or QT prolongation deemed clinically relevant by the investigator - Disease that is considered by the investigator to be rapidly progressing or life threatening such as extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor - History of brain or other CNS metastases - Bilateral diffuse lymphangitic carcinomatosis - Hypokalemia of Grade >1 - History of another primary malignancy within 5 years, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer - Family history of long QT syndrome - Any concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety and anti-tumor activity of the test drug(s) - Patients being treated with drugs recognized being strong or moderate CYP3A4 and/or PgP inhibitors and/or strong CYP3A4 inducers within 2 weeks prior to study entry - Patients received more than two lines of chemotherapy for locally advanced or metastatic breast cancer (For the Phase II: more than one line)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1: Time to progression (TTP), defined as the duration of time from the date of C1V1 until the date of the first objective tumor progression 2: Objective response (OR), defined as complete response (CR) or partial response (PR) (CR + PR) 3: Time to objective response 4: Duration of objective response 5: Clinical benefit (CB), defined as best overall response of complete response (CR) or partial response (PR), or stable disease (SD) >=6 months, or Non-CR/Non-PD for >=6 months (CR + PR + SD6m + Non-CR/Non-PD6m) 6: Duration of clinical benefit;Timepoint(s) of evaluation of this end point: 1: up to 10,8 months 2: up to 10,8 months 3: up to 10,8 months 4: up to 10,8 months 5: up to 10,8 months 6: up to 10,8 months | — |
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Phase I part: To determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2- advanced breast cancer. Phase II part: To evaluate the antitumor activity of BI 836845 in combination with exemestane and everolimus compared to exemestane and everolimus alone in women with HR+/HER2- advanced breast cancer.;Secondary Objective: To determine the safety of BI 836845 in combination with exemestane and everolimus in HR+/HER2- advanced breast cancer patients.;Primary end point(s): 1: Progression-free survival (PFS) 2: occurrence of Dose Limiting Toxicity (DLT) - phase I part;Timepoint(s) of evaluation of this end point: 1: up to 10,8 months 2: up to 28 days | — |
Countries
Austria, Belgium, France, Ireland, Korea, Republic of, Netherlands, Spain, Sweden, Taiwan, United Kingdom
Contacts
Public ContactQRPE PSC CT Information Disclosure
Boehringer Ingelheim Pharma GmbH & Co. KG
Outcome results
None listed